Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine

Heart and Vessels

Volumn 26, Issue 5, 2011, Pages 465-472

  Saitoh, Takeji ^a   Satoh, Hiroshi ^a   Nobuhara, Mamoru ^a   Machii, Masashi ^a   Tanaka, Takamitsu ^a   Ohtani, Hayato ^a   Saotome, Masao ^a   Urushida, Tsuyoshi ^a   Katoh, Hideki ^a   Hayashi, Hideharu ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Contrast induced nephropathy; Glutathione; N acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BIOLOGICAL MARKER; CONTRAST MEDIUM; CREATININE; DIAGNOSTIC AGENT; GLUTATHIONE; LIPID PEROXIDE;

AGED; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; KIDNEY; KIDNEY DISEASE; LIPID PEROXIDATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; URINE;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; ANALYSIS OF VARIANCE; ANTIOXIDANTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; GLUTATHIONE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; OXIDATIVE STRESS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879789779     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-010-0078-0     Document Type: Article

References (43)

1. Kimura T, Morimoto T, Furukawa Y, Kita T (2009) Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J 73:1518-1522
2. Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, DeFranco AC, Eagle KA, McGinnity JG, Patel K, Maxwell-Eward A, Bondie D, Moscucci M (2002) Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 90:1068-1073 (Pubitemid 35335595)
3. Murphy SW, Barrett BJ, Parfrey PS (2000) Contrast nephropathy. J Am Soc Nephrol 11:177-182 (Pubitemid 30020439)
4. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143-149 (Pubitemid 19033091)
5. Rich MW, Crecelius CA (1990) Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 150:1237-1242 (Pubitemid 20188457)
6. Tepel M, Aspelin P, Lameire N (2006) Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 113:1799-1806 (Pubitemid 43958473)
7. Fishbane S, Durham JH, Marzo K, Rudnik M (2004) N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 15:251-260 (Pubitemid 38140765)
8. Gleeson TG, Bulugahapitiya S (2004) Contrast-induced nephropathy. Am J Roentgenol 183:1673-1689 (Pubitemid 44210538)
9. Maeder M, Klein M, Fehr T, Rickli H (2004) Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44:1763-1771 (Pubitemid 39424073)
10. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103:368-375 (Pubitemid 27506242)
11. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259-2264 (Pubitemid 34535335)
12. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr (1990) Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 258:F115-F120 (Pubitemid 20063077)
13. Yoshioka T, Fogo A, Beckman JK (1992) Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 41:1008-1015
14. Detrenis S, Meschi M, Musini S, Savazzi G (2005) Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transpl 20:1542-1550 (Pubitemid 41418575)
15. Persson PB, Hansell P, Lis P (2005) Pathophysiology of contrast medium-induced nephropathy. Kidney Int 68:14-22 (Pubitemid 43181360)
16. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL (2006) N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354:2773-2782 (Pubitemid 43974195)
17. Abbott WA, Bridges RJ, Meister A (1984) Extracellular metabolism of glutathione accounts for its disappearance from the basolateral circulation of the kidneys. J Biol Chem 259:15393-15400 (Pubitemid 15193765)
18. Lash LH (2005) Role of glutathione transport processes in kidney function. Toxicol Appl Pharmacol 204:329-342
19. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
20. Aebi S, Assereto R, Lauterburg BH (1991) High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest 21:103-110
21. Oriana S, Böhm S, Spatti G, Zunino F, Di Re F (1987) A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity. Tumori 73:337-340
22. Girotti AW (1998) Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 39:1529-1542
23. Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K (2008) Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J 72:1499-1505
24. Zhou H, Kato A, Miyaji T, Yasuda H, Fujigaki Y, Yamamoto T, Yonemura K, Takebayashi S, Mineta H, Hishida A (2006) Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. Nephrol Dial Transpl 21:616-623 (Pubitemid 43372906)
25. Yenicerioglu Y, Yilmaz O, Sarioglu S, Ormen M, Akan P, Celik A, Camsari T (2006) Effects of N-acetylcysteine on radiocontrast nephropathy in rats. Scand J Urol Nephrol 40:63-69 (Pubitemid 43207217)
26. Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93:29-34
27. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE, Investigators of the CARE Study (2007) Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115:3189-3196 (Pubitemid 47012233)
28. Thomsen HS, Morcos SK, Erley CM, Grazioloi L, Bonomo L, Ni Z (2008) The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and idoixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 43:170-178 (Pubitemid 351643143)
29. Murphy MB, Murray C, Shorten GD (2001) Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345:1548-1557 (Pubitemid 33144922)
30. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Focaccio A, Ricciardelli B (2004) N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44:762-765 (Pubitemid 39099569)
31. Sankar D, Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR (2009) Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and metaanalysis. Am J Kidney Dis 53:617-627
32. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C (2003) Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362:598-603 (Pubitemid 37013299)
33. Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araújo A, Röedel AP, Caramori AP, Brito FS Jr, Bezerra HG, Nery P, Brizolara A (2005) N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91:774-778 (Pubitemid 40769223)
34. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE (2003) Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 146:E23
35. Harada D, Naito S, Kawauchi Y, Ishikawa K, Koshitani O, Hiraoka I, Otagiri M (2001) Determination of reduced, proteinunbound, and total concentrations of N-acetyl-L-cysteine and L-cysteine in rat plasma by postcolumn ligand substitution high-performance liquid chromatography. Anal Biochem 290:251-259 (Pubitemid 32217536)
36. Olsson B, Johansson M, Gabrielsson J, Bolme P (1988) Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34:77-82 (Pubitemid 18079472)
37. Scaduto RC Jr, Gattone VH 2nd, Martin LF, Yang HC (1991) Elevation of renal glutathione enhances ischemic injury. Ren Physiol Biochem 14:259-270
38. Prasad A, Andrews NP, Padder FA, Husain M, Quyyumi AA (1999) Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J Am Coll Cardiol 34:507-514
39. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O (1989) Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70:89-101 (Pubitemid 19161217)
40. Tofanetti O, Cavalletti E, Besati A, Pratesi G, Pezzoni G, Zunino F (1985) Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent. Cancer Chemother Pharmacol 14:188-193 (Pubitemid 15118636)
41. Zager RA, Johnson AC, Hanson SY (2003) Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int 64:128-139 (Pubitemid 36714165)
42. Bohm S, Oriana S, Spatti G, Di Re F, Breasciani G, Pirovano C, Grosso I, Martini C, Caraceni A, Pilotti S, Zunino F (1999) Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology 57:115-120 (Pubitemid 29385488)
43. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, Di Sciascio G (2008) Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 101:279-285 (Pubitemid 351162953)